Work

Abstract P2-11-03: Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBC): Interim analysis from the multicenter, open-label, phase II control trial

Year: 2017

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs16-p2-11-03

Authors: C Barcenas, E Olek, D Hunt, D Tripathy, E Ibrahim, M Wilkinson, S Hurvitz, N Iannotti, A Kellum, Y Manalo, S Wong, V Hansen, R Alvarez, A Chan, I Gore, D Kendall, J Wade, R Ruiz, P Fang, R Bryce, S Moran

Institutions: The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, Beaver Medical Group, Decatur Memorial Hospital, Rutgers Cancer Institute

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2594304128

Cites:

Cited by: 5

Related to: 10